Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADCT-601 (Univ. of California San Francisco): sourced facts only. name: "We investigated mipasetamab uzoptirine (ADCT-601), an AXL-targeting antibody-drug conjugate (ADC) with pyrrolobenzodiazepine dimer payload, in preclinical models of ACC." [PMID:42179207]; target: "We investigated mipasetamab uzoptirine (ADCT-601), an AXL-targeting antibody-drug conjugate (ADC) with pyrrolobenzodiazepine dimer payload, in preclinical models of ACC." [PMID:42179207]; developer: "Department of Otolaryngology Head and Neck Surgery, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California." [PMID:42179207]; modality: "We investigated mipasetamab uzoptirine (ADCT-601), an AXL-targeting antibody-drug conjugate (ADC) with pyrrolobenzodiazepine dimer payload, in preclinical models of ACC." [PMID:42179207]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ADCT-601 (Univ. of California San Francisco).